These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9693163)

  • 1. Neurohormonal activation in the treatment of congestive heart failure: basis for new treatments?
    Pool PE
    Cardiology; 1998 Jul; 90(1):1-7. PubMed ID: 9693163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of neurohormonal activation.
    Pool PE
    Clin Ther; 1997; 19 Suppl A():53-73. PubMed ID: 9385505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications.
    Dávila DF; Núñez TJ; Odreman R; de Dávila CA
    Int J Cardiol; 2005 Jun; 101(3):343-6. PubMed ID: 15907399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of calcium antagonists in a rat model of heart failure.
    Mulder P; Richard V; Thuillez C
    Cardiology; 1998; 89 Suppl 1():33-7. PubMed ID: 9570427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurohumoral aspects of heart failure.
    Benedict CR
    Cardiol Clin; 1994 Feb; 12(1):9-23. PubMed ID: 7910114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurohormonal activation in congestive heart failure and the role of vasopressin.
    Chatterjee K
    Am J Cardiol; 2005 May; 95(9A):8B-13B. PubMed ID: 15847852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurohormonal systems during progression of heart failure: a review.
    Svanegaard J; Johansen JB; Thayssen P; Haghfelt T
    Cardiology; 1993; 83(1-2):21-9. PubMed ID: 7903208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of calcium antagonists in patients with congestive heart failure.
    Katz S
    Clin Ther; 1997; 19 Suppl A():92-113. PubMed ID: 9385507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurohormonal activation in heart failure with reduced ejection fraction.
    Hartupee J; Mann DL
    Nat Rev Cardiol; 2017 Jan; 14(1):30-38. PubMed ID: 27708278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.
    Packer M
    Circulation; 1989 Dec; 80(6 Suppl):IV59-67. PubMed ID: 2688986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms.
    Packer M
    J Intern Med; 1996 Apr; 239(4):327-33. PubMed ID: 8774387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuro-hormonal mechanisms in heart insufficiency--from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; de Faria DB
    Rev Port Cardiol; 1989 Feb; 8(2):129-48. PubMed ID: 2576635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).
    Levine TB
    Clin Cardiol; 1997 Apr; 20(4):320-6. PubMed ID: 9098588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurohumoral axis in congestive heart failure.
    Francis GS; Goldsmith SR; Levine TB; Olivari MT; Cohn JN
    Ann Intern Med; 1984 Sep; 101(3):370-7. PubMed ID: 6147109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving role of calcium channel blockers in heart failure.
    Pieper JA
    Pharmacotherapy; 1996; 16(2 Pt 2):43S-49S. PubMed ID: 8668605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurohumoral control mechanisms in congestive heart failure.
    Cohn JN; Levine TB; Francis GS; Goldsmith S
    Am Heart J; 1981 Sep; 102(3 Pt 2):509-14. PubMed ID: 6115571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.